Dyadic International Inc. (NASDAQ:DYAI) Sees Large Increase in Short Interest

Dyadic International Inc. (NASDAQ:DYAI) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 67,368 shares, a growth of 25.7% from the November 30th total of 53,615 shares. Based on an average daily volume of 793,284 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the company’s shares are short sold. Approximately 0.3% of the company’s shares are short sold. Based on an average daily volume of 793,284 shares, the short-interest ratio is presently 0.1 days.

Dyadic International Trading Down 1.5%

Shares of DYAI opened at $0.88 on Wednesday. Dyadic International has a 12 month low of $0.71 and a 12 month high of $2.14. The stock’s 50-day moving average is $0.98 and its two-hundred day moving average is $0.99. The company has a debt-to-equity ratio of 1.92, a current ratio of 2.85 and a quick ratio of 2.85. The stock has a market cap of $31.73 million, a PE ratio of -3.65 and a beta of 1.24.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%. The company had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.22 million. Equities analysts forecast that Dyadic International will post -0.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. HC Wainwright began coverage on shares of Dyadic International in a research note on Thursday, October 23rd. They set a “buy” rating and a $3.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Monday. Finally, Craig Hallum assumed coverage on Dyadic International in a research note on Monday, September 8th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.00.

Institutional Investors Weigh In On Dyadic International

A number of large investors have recently added to or reduced their stakes in DYAI. Bank of America Corp DE lifted its holdings in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares in the last quarter. Marathon Capital Management purchased a new stake in shares of Dyadic International during the third quarter worth about $41,000. Chapin Davis Inc. lifted its stake in shares of Dyadic International by 4.7% in the second quarter. Chapin Davis Inc. now owns 882,849 shares of the biotechnology company’s stock worth $874,000 after acquiring an additional 40,000 shares in the last quarter. AlphaCore Capital LLC purchased a new position in Dyadic International in the second quarter valued at about $50,000. Finally, Truist Financial Corp grew its stake in Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares in the last quarter. 27.95% of the stock is owned by institutional investors and hedge funds.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.